Market Overview

JP Morgan Comments on Potential Combination Of Valeant And Zoetis, Remains Overweight VRX and Neutral on ZTS

Related VRX
Benzinga's Option Alert Recap From May 17
Jim Cramer Weighs In On Valeant, Corning And Synergy Pharmaceuticals
Related ZTS
Benzinga's Top Upgrades, Downgrades For May 26, 2017
Watch These 7 Huge Put Purchases In Friday Trade

The bank sees Zoetis as an 'attractive, durable, cash-pay business to Valeant's portfolio' and that a deal would be minimal accretive to EPS in the next 12 months. However, the deal would bring benefits in the longer run by aiding multiple expansion. Synergies remain elusive to those trying to identify them

Latest Ratings for VRX

Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight
Nov 2016MizuhoDowngradesNeutralUnderperform
Nov 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Analyst Color Reiteration Analyst Ratings


Related Articles (VRX + ZTS)

View Comments and Join the Discussion!